Statutory Accounts for the Full Year Ended 30 June 2020
Filed with ASX · · 118 pages · English
VP Investor Relations P: +61 3 9389 3407 E: mark.dehring@csl.com.au Media: Jemimah Brennan Head of Communications, Asia Pacific P: +61 412 635 483 E: jemimah.brennan@csl.com.au Lodged with the ASX under Listing Rule 4.3A. Contents (Previous corresponding period: Year ended 30 June 2019) Reported • Sales revenue up 7.2% to US$8.8 billion. • Net profit after tax for the year attributable to members
Earlier from CSL
- CSL to acquire LateStage Gene Therapy Candidate from uniQure
- Change in Leadership of CSLs Finance Function
- New Debt Facilities to Strengthen Maturity Profile
- CSL Statutory Accounts for the Half Year Ended 31/12/2019
- Research and Development Investor Briefing 2019
Later from CSL
- CSL Supply Agreement for UQ Vaccine with Commonwealth
- Chairmans Address to Shareholders
- Update on UQ-CSL v451 COVID-19 Vaccine
- Dividend/Distribution - CSL
- Statutory Accounts for the Half Year Ended 31 Dec 2020
Follow CSL into a list and get an email when it puts out news.
Follow CSL